Anti-LIMD1 [3F2/G6]
Invented by Dr Tyson Sharp at University College London
- Datasheet
- References (2)
- Inventor Info
Info
Catalogue Number | 151611 |
Applications | ELISA IHC IF IP WB |
Antigen/Gene or Protein Targets | LIM domains-containing protein 1 (LIMD1) |
Reactivity | Human |
Relevance | LIMD1 (LIM domain-containing protein 1) is part of the zyxin/ajuba family of proteins and is a ubiquitously expressed tumour suppressor containing three LIM zinc-binding domains. LIMD1 may be involved in cell anchoring via focal adhesions and in the cell cycle, particularly during mitosis. Limd1 interacts with the proteins SQSTM1, Rb, p62 and TRAF6. Limd1 was first identified when the deletion of its gene was noted in some cervical cancers, and it has since been noted to be downregulated in lung and breast cancers. |
Host | Mouse |
Immunogen | Recombinant LIMD1 |
Positive Control | H1299 cell lysate |
Subclass | IgG1 |
Myeloma Used | P3X63Ag8.653 |
Strain | Balb/c |
Research Area | Cancer, Epigenetics & Nuclear Signalling |
References: 2 entries
Foxler et al. 2018. EMBO Mol Med. 10(8):. PMID: 29930174.
A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia.
Europe PMC ID: 29930174
Add a reference
References: 2 entries
Foxler et al. 2018. EMBO Mol Med. 10(8):. PMID: 29930174.
A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia.
Add a reference